Retatrutide - (2381089-83-2)

Retatrutide – (2381089-83-2)

Retatrutide (LY-3437943) is an experimental drug developed by Eli Lilly for the treatment of obesity. It is a triple agonist targeting the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R).

In a phase 2 trial, retatrutide demonstrated a mean weight reduction of over 17.5% in adults with obesity or preobesity without diabetes. The drug is a peptide with a specific amino acid sequence and unique chemical modifications, including 2-aminoisobutyric acid, alpha-methyl leucine, and a modified lysine tail.

Retatrutide has shown efficacy in improving glucose tolerance and causing significant body weight loss through glucagon receptor activation. It is currently being investigated in phase 3 clinical trials, with results indicating its potential to outperform existing obesity treatments in terms of total weight loss.

The drug’s safety profile is similar to other GLP-1 and GIP-GLP-1 receptor agonists, with mostly mild to moderate gastrointestinal adverse events reported during dose escalation. Retatrutide’s ability to achieve substantial weight reduction and improve cardiometabolic measures makes it a promising candidate for obesity treatment.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

SKU: 2381089-83-2

Categories: Biochemical, Nootropic

Tags: GCGR), GIP, Obesity treatment, Triple glucagon hormone receptor agonist (GLP-1, Type 2 diabetes therapeutic

Description
Additional information

Retatrutide (LY-3437943) is an experimental drug developed by Eli Lilly for the treatment of obesity. It is a triple agonist targeting the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R).

In a phase 2 trial, retatrutide demonstrated a mean weight reduction of over 17.5% in adults with obesity or preobesity without diabetes. The drug is a peptide with a specific amino acid sequence and unique chemical modifications, including 2-aminoisobutyric acid, alpha-methyl leucine, and a modified lysine tail.

Retatrutide has shown efficacy in improving glucose tolerance and causing significant body weight loss through glucagon receptor activation. It is currently being investigated in phase 3 clinical trials, with results indicating its potential to outperform existing obesity treatments in terms of total weight loss.

The drug’s safety profile is similar to other GLP-1 and GIP-GLP-1 receptor agonists, with mostly mild to moderate gastrointestinal adverse events reported during dose escalation. Retatrutide’s ability to achieve substantial weight reduction and improve cardiometabolic measures makes it a promising candidate for obesity treatment.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Retatrutide
https://pubchem.ncbi.nlm.nih.gov/compound/171390338
https://www.medchemexpress.com/retatrutide.html
https://www.nejm.org/doi/full/10.1056/NEJMoa2301972#:~:text=Retatrutide
https://www.sciencedirect.com/science/article/abs/pii/S0014299924007854
https://www.nature.com/articles/s41591-024-03018-2

Other Names	EX-A7826E
IUPAC Name	20-[[(1S)-4-[2-[2-[2-[[(5S)-5-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S, 3R)-2-[[(2S)-2-[[(2S, 3R)-2-[[2-[[(2S)-5-amino-2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-2-methylpropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-2, 4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]-6-[[(2S)-1-[[(2S)-5-amino-1-[[1-[[(2S)-1-[[(2S)-1-[[(3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]amino]-1, 5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-20-oxoicosanoic acid
CAS	2381089-83-2
Molecular Weight	4731
Molecular Formula	C221H342N46O68
SMILES	CC[C@H](C)C(C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N3CCC[C@H]3C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](C)NC(=O)C(C)(C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)CC[C@@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@](C)(CC(C)C)NC(=O)C([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC8=CC=CC=C8)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)C(C)(C)NC(=O)[C@H](CC9=CC=C(C=C9)O)N

No products in the cart.